Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
SHANGHAI, China and CUPERTINO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, announced today that the Company will present an overview of their CAR-T immuno-oncology clinical development programs at the Biotech Showcase™ 2016, taking place in San Francisco, CA, on January 11–13, 2016. As previously announced the Company will also at that time release 48-week clinical data from the Phase IIb trial of its ReJoin® human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The presentations can be viewed via live webcast at the link provided below.
| Conference: | 8th Annual BioTech Showcase 2016 |
| Date: | Tuesday, January 12, 2016 |
| Time: | 10:00 – 10:30 AM PST |
| Title: | Alteration of Knee Osteoarthritis, ReJoin® Phase IIb One Year Follow Up Results |
| and | |
| CAR-T immuno-oncology clinical development program | |
| Location: | Track C - Mission II, 4th Flr, Parc 55, Union Square, 55 Cyril Magnin Street, San Francisco, CA |
| Live webcast: | http://edge.media-server.com/m/p/se69r6oq |
Company management will attend the conference and be available for discussions. To arrange one-to-one meetings with management, please contact [email protected]. The presented material will be available on the Company website following the presentations.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of six independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 [email protected] Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 [email protected]
